Valuation : argenx SE

Market Cap 62.88B 54.11B 50.95B 46.42B 86.86B 5,983B 87.2B 604B 233B 3,048B 236B 231B 9,657B P/E 2026 *
32.4x
P/E 2027 * 26.9x
Enterprise Value 59.17B 50.91B 47.94B 43.68B 81.73B 5,630B 82.05B 568B 220B 2,868B 222B 217B 9,087B EV / Sales 2026 *
9.38x
EV / Sales 2027 * 7.42x
Free-Float
99.99%
Yield 2026 *
0.04%
Yield 2027 * 0.08%

Last Transcript : argenx SE

1 day-0.35%
1 week-5.50%
Current month-1.53%
1 month+12.41%
3 months+13.00%
6 months+34.89%
Current year+20.28%
1 week 842
Extreme 842
909
1 month 723.4
Extreme 723.4
925
Current year 568.4
Extreme 568.4
925
1 year 568.4
Extreme 568.4
925
3 years 271
Extreme 271
925
5 years 224.1
Extreme 224.1
925
10 years 12.5
Extreme 12.5
925
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap. Importance
11/23/25 Sell

Chief Executive Officer

2,000 0.0032%
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Exercice

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
-0.37%-5.50%+31.47%+75.35% 62.88B
-0.94%-0.71%+45.60%+103.25% 68.52B
+3.13%+1.71%-12.50%+390.48% 28.13B
-2.74%-6.55%+26.01%+10.96% 25.56B
-0.54%-5.47%-3.88%-18.31% 24.65B
-1.31%-4.05%+19.16%-18.67% 19.81B
-4.27%+3.07%+211.22%+362.48% 17.69B
-1.37%-4.71%-5.41%+506.15% 14.66B
+1.14%-0.34%+52.38%+163.82% 14.45B
+1.50%+20.14%-6.83%+1,038.96% 13.99B
Average -0.59%+0.55%+35.72%+261.45% 29.04B
Weighted average by Cap. -0.58%-0.81%+34.51%+182.52%

Financials

2026 *2027 *
Net sales 6.31B 5.43B 5.11B 4.65B 8.71B 600B 8.74B 60.55B 23.4B 306B 23.68B 23.16B 968B 7.64B 6.58B 6.19B 5.64B 10.56B 727B 10.6B 73.41B 28.37B 371B 28.7B 28.08B 1,174B
Net income 1.15B 993M 935M 852M 1.59B 110B 1.6B 11.08B 4.28B 55.92B 4.33B 4.24B 177B 2.38B 2.05B 1.93B 1.76B 3.29B 227B 3.3B 22.86B 8.84B 115B 8.94B 8.75B 366B
Net Debt -3.71B -3.19B -3.01B -2.74B -5.13B -353B -5.15B -35.65B -13.78B -180B -13.94B -13.64B -570B -6.19B -5.32B -5.01B -4.57B -8.55B -589B -8.58B -59.42B -22.96B -300B -23.23B -22.73B -950B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-09-10 862.00 -0.37% 3,918
26-09-09 €865.20 -0.07% 74,047
26-09-08 €865.80 -0.41% 46,918
26-09-07 €869.40 -2.71% 81,391
26-09-04 €893.60 -2.06% 55,862
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1,005.46USD
Average target price
1,170.70USD
Spread / Average Target
+16.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!